Nouscom AG logo

Nouscom AG

Nouscom AG is a start-up biotech company dedicated to the development of novel vaccination strategies for cancer immunotherapy. The company is headquartered in Basel, Switzerland and has operations in Rome, Italy.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttp://www.nouscom.com
Disease Focus
STOCK CODENon Listed
Address
Baumleingasse 18, CH-4051
Basel
Switzerland
Email
Contact Number
+41 61 201 18 31

Nouscom AG is a start-up biotech company dedicated to the development of novel vaccination strategies for cancer immunotherapy. The company is headquartered in Basel, Switzerland and has operations in Rome, Italy.

Nouscom is founded by senior team of Okairos (acquired by GlaxoSmithKline in 2013) that has worked together for many years, and are veterans in the field of oncolytic and genetic vaccines.

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://in.linkedin.com/company/nouscom-ag” connections=”true” suffix=””]

Frameshift peptides,(FSPs) arising due to DNA mismatch repair deficiency in cancer offer a unique opportunity for a preventive cancer vaccine based on neoantigens because they are predictable, shared among many patients and potent immunogens. Nouscom is developing vaccines encoding several FPS in one artificial gene expressed by the viral delivery systems.

In May 2016, Nouscom raised EUR 12 Mn in Series A financing co-led by LSP and Versant Ventures, to support discovery and development of personalized cancer vaccines and tumor selective oncolytic viruses.